Cargando…

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

Radiotherapy (RT) has been used to control tumors by physically damaging DNA and inducing apoptosis; it also promotes antitumor immune responses via neoantigens release and augmenting immune-oncology agents to elicit systemic response. Tumor regression after RT can recruit inflammatory cells, such a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Younes, Ahmed I., Barsoumian, Hampartsoum B., Sezen, Duygu, Verma, Vivek, Patel, Roshal, Wasley, Mark, Hu, Yun, Dunn, Joe D., He, Kewen, Chen, Dawei, Menon, Hari, Masrorpour, Fatemeh, Gu, Meidi, Yang, Liangpeng, Puebla-Osorio, Nahum, Cortez, Maria Angelica, Welsh, James W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750418/ https://www.ncbi.nlm.nih.gov/pubmed/33340886 http://dx.doi.org/10.1016/j.tranon.2020.100983

Ejemplares similares

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model
por: Hu, Yun, et al.
Publicado: (2021)

Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer
por: He, Kewen, et al.
Publicado: (2021)

Pulsed radiotherapy to mitigate high tumor burden and generate immune memory
por: Sezen, Duygu, et al.
Publicado: (2022)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
por: Hu, Yun, et al.
Publicado: (2022)

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
por: Chen, Dawei, et al.
Publicado: (2020)

Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches
por: Klein, Katherine, et al.
Publicado: (2020)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2023)

Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance
por: Ganjoo, Shonik, et al.
Publicado: (2022)

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
por: Chen, Dawei, et al.
Publicado: (2020)

Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases
por: He, Kewen, et al.
Publicado: (2021)

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
por: Barsoumian, Hampartsoum B, et al.
Publicado: (2020)

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

Bone morphogenetic protein 7 promotes resistance to immunotherapy
por: Cortez, Maria Angelica, et al.
Publicado: (2020)

The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
por: Ganjoo, Shonik, et al.
Publicado: (2023)

Radiation and Anti-Cancer Vaccines: A Winning Combination
por: Cadena, Alexandra, et al.
Publicado: (2018)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
por: Hu, Yun, et al.
Publicado: (2022)

Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection
por: Hu, Yun, et al.
Publicado: (2023)

Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
por: Schoenhals, Jonathan E., et al.
Publicado: (2018)

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4(+)CD25(+)FoxP3(+) T Regulatory Cell Suppression
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2016)

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
por: Menon, Hari, et al.
Publicado: (2019)

Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell
por: El Rami, Fadi E., et al.
Publicado: (2020)

Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
por: Menon, Hari, et al.
Publicado: (2019)

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report
por: He, Kewen, et al.
Publicado: (2023)

Absence of p53-Dependent Apoptosis Combined With Nonhomologous End-Joining Deficiency Leads to a Severe Diabetic Phenotype in Mice
por: Tavana, Omid, et al.
Publicado: (2010)

Platelet-Activating Factor Induces Epigenetic Modifications in Human Mast Cells
por: Damiani, Elisabetta, et al.
Publicado: (2015)

DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model
por: Van Nguyen, Thang, et al.
Publicado: (2007)

Ku70 Functions in Addition to Nonhomologous End Joining in Pancreatic β-Cells: A Connection to β-Catenin Regulation
por: Tavana, Omid, et al.
Publicado: (2013)

Platelet activating factor-induced expression of p21 is correlated with histone acetylation
por: Damiani, Elisabetta, et al.
Publicado: (2017)

Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib
por: Gao, Ningning, et al.
Publicado: (2016)

Induction of B-cell lymphoma by UVB Radiation in p53 Haploinsufficient Mice
por: Puebla-Osorio, Nahum, et al.
Publicado: (2011)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
por: Kortylewski, Marcin, et al.
Publicado: (2014)

Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
por: Ren, Sumei, et al.
Publicado: (2022)

Natural Xylooligosaccharides Exert Antitumor Activity via Modulation of Cellular Antioxidant State and TLR4
por: Batsalova, Tsvetelina, et al.
Publicado: (2022)

TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects
por: Haderski, Gary J., et al.
Publicado: (2020)

Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors
por: Díaz-Carballo, David, et al.
Publicado: (2021)

Tumor immune microenvironment (TIME) to enhance antitumor immunity
por: Rajbhandary, Sajin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2pcmpt74qghhhbc3ttiuq753is